Characteristics of Patients with Type 2 Diabetes Mellitus Receiving Treatment with Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory Data

Trial Identifier: D1690R00034
Sponsor: AstraZeneca
Collaborator:
Optum
Start Date: March 2017
Primary Completion Date: April 2017
Study Completion Date: May 2017
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
USA, DE Wilmington, DE, USA, 19803